Global HGH Biosimilars Market Size By Type (Clinical, Experiment), By Application (Treament, Prevention), By Region, And Segment Forecasts, 2023 to 2032

The Global HGH (Human Growth Hormone) Biosimilars Market was valued at USD 1.4 billion in 2023 and is projected to reach USD 3.2 billion by 2031, growing at a CAGR of 10.7% during the forecast period from 2023 to 2031. The market’s expansion is driven by the rising incidence of growth hormone deficiency disorders, increasing healthcare affordability, and growing acceptance of biosimilars as cost-effective alternatives to branded biologics. Technological advancements in recombinant DNA technology and regulatory approvals across regions are further catalyzing market growth.

Drivers:

Increasing Incidence of Growth Hormone Disorders

With the rising prevalence of conditions like growth hormone deficiency (GHD), Turner syndrome, and chronic kidney disease-induced short stature, the demand for HGH therapies is growing, thereby propelling biosimilar uptake.

Cost-Effectiveness of Biosimilars

HGH biosimilars offer similar efficacy and safety at a reduced cost compared to originator biologics. This affordability drives their adoption among healthcare providers and patients, especially in emerging markets.

Patent Expirations of Reference Biologics

The expiration of patents for several branded HGH products is paving the way for biosimilar manufacturers to enter the market with competitive pricing, accelerating market penetration.

Restraints:

Stringent Regulatory Pathways

Despite biosimilars’ advantages, navigating the complex and rigorous regulatory approval processes poses a challenge for market players, especially in the U.S. and Europe.

Limited Physician Awareness and Acceptance

In some regions, there is limited awareness or reluctance among healthcare professionals to prescribe biosimilars due to concerns over interchangeability and long-term efficacy.

Opportunity:

Emerging Markets and Expanding Healthcare Access

The increasing investment in healthcare infrastructure and the expansion of insurance coverage in Asia-Pacific and Latin America offer lucrative opportunities for HGH biosimilar manufacturers.

Technological Advancements in Biomanufacturing

Improvements in production techniques such as cell line engineering and protein expression systems are enabling the development of more stable and effective HGH biosimilars, enhancing their market appeal.

Market by System Type Insights:

Based on system type, the Recombinant Human Growth Hormone Biosimilars segment held the largest market share in 2023. This segment dominates due to its wide therapeutic applications, proven clinical efficacy, and growing regulatory approvals.

Market by End-use Insights:

In terms of end-use, the Pediatric Patients segment was the leading revenue generator in 2023. The rising prevalence of pediatric growth hormone deficiencies and favorable reimbursement scenarios make this segment the primary driver of HGH biosimilar consumption.

Market by Regional Insights:

Geographically, North America accounted for the largest market share in 2023, attributed to the high healthcare expenditure, growing biosimilar adoption, and supportive regulatory framework. However, Asia-Pacific is projected to exhibit the highest CAGR during the forecast period, owing to expanding healthcare access, increased awareness, and the presence of large patient pools.

Competitive Scenario:

Prominent players in the Global HGH Biosimilars Market include Biocon Biologics, Sandoz (a Novartis Division), Pfizer Inc., Teva Pharmaceutical Industries Ltd., LG Chem, and GeneScience Pharmaceuticals. These companies are leveraging strategic alliances, R&D investments, and regulatory approvals to solidify their presence. Noteworthy developments include:

In 2023, Biocon Biologics launched a next-generation HGH biosimilar in Latin America, expanding its global footprint.

Sandoz received U.S. FDA approval in 2024 for its HGH biosimilar, marking a critical milestone for its U.S. market expansion.

LG Chem announced a strategic collaboration in 2025 with a biotech startup to co-develop long-acting HGH biosimilars, enhancing treatment adherence.

Scope of Work – Global HGH Biosimilars Market

Key Market Developments:

2023: Biocon Biologics introduced a new recombinant HGH biosimilar targeting pediatric GHD in Southeast Asia.

2024: Pfizer filed for EMA approval of its latest long-acting HGH biosimilar.

2025: Sandoz entered into a supply agreement with a leading hospital chain in Europe to promote biosimilar uptake.

FAQs:

1) What is the current market size of the Global HGH Biosimilars Market?

The market was valued at USD 1.4 billion in 2023.

2) What is the major growth driver of the Global HGH Biosimilars Market?

The major driver is the rising incidence of growth hormone deficiencies coupled with the cost advantage of biosimilars.

3) Which is the largest region during the forecast period in the Global HGH Biosimilars Market?

North America currently leads the market, but Asia-Pacific is anticipated to witness the highest growth rate.

4) Which segment accounted for the largest market share in the Global HGH Biosimilars Market?

The Recombinant HGH Biosimilars segment accounted for the largest market share by system type in 2023.

5) Who are the key market players in the Global HGH Biosimilars Market?

Key players include Biocon Biologics, Sandoz, Pfizer Inc., Teva Pharmaceuticals, LG Chem, and GeneScience Pharmaceuticals.